At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 92 enrolled
Drug / intervention
Brimonidine tartrate was applied cutaneously once daily for 8 days. +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea
In Brief
A Phase 3 clinical trial evaluating Brimonidine tartrate was applied cutaneously once daily for 8 days. and Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days. for Rosacea and Erythema. Completed, enrolled 92 participants across 14 sites in 3 countries.
Detailed Summary
The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.
Study Details
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJul 2013
Primary CompletionNov 2013
TodayJul 2026
First PostedJun 24, 2013
Enrollment StartJul 1, 2013
Primary CompletionNov 14, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.0 years ago
Interventions
Brimonidine tartrate was applied cutaneously once daily for 8 days.drug
Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.drug